Sanofi to Collaborate With BioNTech on Coronavirus Vaccine Production
January 27 2021 - 2:18AM
Dow Jones News
By Cecilia Butini
Sanofi SA said Wednesday that it has entered into an agreement
with BioNTech SE to support the manufacture and supply of the
coronavirus vaccine that it is co-developing with Pfizer Inc.
The French pharmaceutical major said it will provide BioNTech
with access to its production infrastructure to supply more than
125 million vaccine doses to the European Union. Initial supplies
will come from Sanofi's sites in Frankfurt from the summer 2021, it
said.
Sanofi added that it is continuing the development of two
vaccine candidates against Covid-19, saying that in February 2021
it plans to initiate a new Phase 2 study of the recombinant
protein-based vaccine that it is developing with GlaxoSmithKline
PLC. The company is also developing a messenger-RNA vaccine in
partnership with Translate Bio Inc., it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
January 27, 2021 02:03 ET (07:03 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
